JP2021523125A5 - - Google Patents
Info
- Publication number
- JP2021523125A5 JP2021523125A5 JP2020561786A JP2020561786A JP2021523125A5 JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5 JP 2020561786 A JP2020561786 A JP 2020561786A JP 2020561786 A JP2020561786 A JP 2020561786A JP 2021523125 A5 JP2021523125 A5 JP 2021523125A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- therapeutic pharmaceutical
- receptor agonist
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862666675P | 2018-05-03 | 2018-05-03 | |
| US62/666,675 | 2018-05-03 | ||
| IN201841019588 | 2018-05-25 | ||
| IN201841019588 | 2018-05-25 | ||
| PCT/US2019/030652 WO2019213558A1 (en) | 2018-05-03 | 2019-05-03 | Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021523125A JP2021523125A (ja) | 2021-09-02 |
| JP2021523125A5 true JP2021523125A5 (https=) | 2022-05-13 |
| JP7458032B2 JP7458032B2 (ja) | 2024-03-29 |
Family
ID=68386694
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020561786A Active JP7458032B2 (ja) | 2018-05-03 | 2019-05-03 | 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20210169978A1 (https=) |
| EP (2) | EP4364811A3 (https=) |
| JP (1) | JP7458032B2 (https=) |
| CN (1) | CN112469474A (https=) |
| AU (1) | AU2019262612B2 (https=) |
| BR (1) | BR112020022395A2 (https=) |
| ES (1) | ES2978951T3 (https=) |
| PL (1) | PL3813942T3 (https=) |
| WO (1) | WO2019213558A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2010241564B2 (en) | 2009-04-30 | 2014-07-31 | Midwestern University | Novel therapeutic treatments using centhaquin |
| WO2022240964A1 (en) * | 2021-05-11 | 2022-11-17 | Pharmazz, Inc. | Pharmaceutical composition and method for treatment of acute respiratory distress syndrome (ards) in corona virus disease (covid-19) |
| US20240207356A1 (en) * | 2022-12-26 | 2024-06-27 | Pharmazz, Inc. | Composition and method for wound healing and repair of damaged nerves |
| US20240382461A1 (en) * | 2023-05-15 | 2024-11-21 | Pharmazz, Inc. | Pharmaceutical composition and method for prevention and treatment of hearing loss |
| IN202411028038A (https=) * | 2024-04-04 | 2025-05-23 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0597891A (ja) * | 1991-04-24 | 1993-04-20 | Banyu Pharmaceut Co Ltd | 血管弛緩ペプチド類 |
| CA2578709C (en) * | 2004-06-17 | 2010-06-15 | Virun, Inc. | Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents |
| JP2009506119A (ja) * | 2005-08-31 | 2009-02-12 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置 |
| US9829494B2 (en) * | 2005-12-01 | 2017-11-28 | Adrenomed Ag | Methods of treatment using ADM antibodies |
| AU2008232425A1 (en) * | 2007-04-02 | 2008-10-09 | Auspex Pharmaceuticals, Inc. | Substituted pyrimidines |
| CN101730694A (zh) * | 2007-04-10 | 2010-06-09 | 奥斯拜客斯制药有限公司 | 用于治疗高血压的取代的氘富集的噻吩 |
| EP2545920A1 (en) | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapy for complications of diabetes |
| AU2010241564B2 (en) * | 2009-04-30 | 2014-07-31 | Midwestern University | Novel therapeutic treatments using centhaquin |
| WO2012070040A1 (en) * | 2010-11-26 | 2012-05-31 | Technion Research And Development Foundation Ltd | Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury |
| CN110354267A (zh) * | 2012-08-31 | 2019-10-22 | 法尔麦兹公司 | 用于低血压复苏的方法和组合物 |
| WO2015006324A2 (en) | 2013-07-08 | 2015-01-15 | Midwesterern University | Compositions and methods for treating neuropsychiatric disorders using an endothelin-b receptor agonist |
-
2019
- 2019-05-03 BR BR112020022395-6A patent/BR112020022395A2/pt not_active Application Discontinuation
- 2019-05-03 PL PL19796519.7T patent/PL3813942T3/pl unknown
- 2019-05-03 JP JP2020561786A patent/JP7458032B2/ja active Active
- 2019-05-03 CN CN201980038669.0A patent/CN112469474A/zh active Pending
- 2019-05-03 ES ES19796519T patent/ES2978951T3/es active Active
- 2019-05-03 AU AU2019262612A patent/AU2019262612B2/en active Active
- 2019-05-03 US US17/052,473 patent/US20210169978A1/en active Pending
- 2019-05-03 EP EP24163271.0A patent/EP4364811A3/en active Pending
- 2019-05-03 WO PCT/US2019/030652 patent/WO2019213558A1/en not_active Ceased
- 2019-05-03 EP EP19796519.7A patent/EP3813942B1/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021523125A5 (https=) | ||
| Wilson | Clinical pharmacokinetics of teicoplanin | |
| JP2013532635A (ja) | トロンボキサン−ａ２受容体アンタゴニストでの肝腎症候群および肝性脳症の治療方法 | |
| HUP0104085A2 (hu) | Vazopresszin antagonisták alkalmazása pulmonáris hipertenzió kezelésére szolgáló gyógyszerkészítmények előállítására | |
| JP2021523125A (ja) | 出血およびセンタキンによる蘇生後のエンドセリン受容体の変化 | |
| NZ532158A (en) | Combinations comprising cox-2 inhibitors and aspirin | |
| ES3043583T3 (en) | Dapagliflozin for use in methods of treating chronic kidney disease | |
| US20260102472A1 (en) | Semaglutide in medical therapy | |
| JP2004538319A5 (https=) | ||
| Seaton et al. | Possible potentiation of warfarin by fluconazole | |
| Honda et al. | Thrombotic microangiopathy associated with alpha-interferon therapy for chronic myelocytic leukemia | |
| US20090285909A1 (en) | Lactate and Calcium Containing Pharmaceutical Composition and Uses Thereof | |
| JP2021531297A5 (https=) | ||
| JP2002326936A5 (https=) | ||
| CN102091052B (zh) | 双环醇双层渗透泵控释片剂及其制备方法 | |
| Munger | New agents for managing hyponatremia in hospitalized patients | |
| KR101210831B1 (ko) | 폴리에틸렌글리콜과 비타민 씨를 함유하는 장관 하제 조성물 | |
| JP2002505678A (ja) | 腫瘍組織を選択的に制御するための、相乗効果を有する組成物 | |
| Gierer et al. | Activated protein C reduces tissue hypoxia, inflammation, and apoptosis in traumatized skeletal muscle during endotoxemia | |
| US4798811A (en) | Combination preparation | |
| Schernthaner et al. | Glucose-lowering therapy in type 2 diabetes: New hope after the EMPA-REG outcome trial | |
| WO2017037737A1 (en) | Parenteral formulations of levosimendan | |
| WO2007129618A1 (ja) | 好中球の活性化および遊走因子の抑制剤およびその利用 | |
| JP2008533109A (ja) | 利尿を促進するための複合治療 | |
| US20070032557A1 (en) | Method for administering levosimendan |